|
|
| Product Name: | ZLc002 | | Synonyms: | L-Valine, N-(3-methoxy-1,3-dioxopropyl)-, methyl ester;EX-A5758;EX A5758,EXA5758;ZLc002;(S)-ZLc002 | | CAS: | 308277-46-5 | | MF: | C10H17NO5 | | MW: | 231.25 | | EINECS: | | | Product Categories: | | | Mol File: | 308277-46-5.mol |  |
| | ZLc002 Chemical Properties |
| Boiling point | 350.1±22.0 °C(Predicted) | | density | 1.115±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 46 mg/mL (198.92 mM);Ethanol: 46 mg/mL (198.92 mM) | | pka | 12.22±0.46(Predicted) | | Water Solubility | Water: 46 mg/mL (198.92 mM) | | InChI | InChI=1S/C10H17NO5/c1-6(2)9(10(14)16-4)11-7(12)5-8(13)15-3/h6,9H,5H2,1-4H3,(H,11,12)/t9-/m0/s1 | | InChIKey | BWPKYDAJBOUZDX-VIFPVBQESA-N | | SMILES | C(OC)(=O)[C@H](C(C)C)NC(=O)CC(OC)=O |
| | ZLc002 Usage And Synthesis |
| Biological Activity | ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. | | Biological Functions | ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability. It could disrupt binding between nNOS and NOS1AP using ex-vivo, in vitro, and purified recombinant systems. In vitro, ZLc002 reduced coimmunoprecipitation of full-length NOS1AP and nNOS in cultured neurons and HEK293T cells co-expressing full-length nNOS and NOS1AP[1]. | | References |
[1] Lee WH, et al. Mol Pain. 2018 Jan-Dec;14:1744806918801224.
[2] Wan-Hung Lee. “ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability.” Molecular Pain 14 (2018): 1744806918801224.
|
| | ZLc002 Preparation Products And Raw materials |
|